Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, ...

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Verve Therapeutics (VERV) to $15 from $14 and keeps a Buy rating on ...

EXCLUSIVE: Verve Ventures, Verve’s film financing and sales division, has boarded Good Boy to represent worldwide rights, ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

EXCLUSIVE: Verve has welcomed agent Barrett Bischoff to its Talent team and promoted Lacey Hunsucker to Talent Agent. In his ...

AI, human and cultural understanding business Verve has named Peter Latham as director as part of 11 promotions at the ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verve Therapeutics (VERV – Research Report), ...

Verve Therapeutics Inc. (VERV) on Thursday reported a loss of $50 million in its fourth quarter. The Boston-based company said it had a loss of 58 cents per share. The results beat Wall Street ...